Breaking News Instant updates and real-time market news.

MYL

Mylan

$44.54

0.23 (0.52%)

, ABT

Abbott

$58.99

0.17 (0.29%)

07:32
01/08/18
01/08
07:32
01/08/18
07:32

Mylan to complete $1B share repurchase plan

Mylan (MYL) announced that it is completing its previously-approved $1B share repurchase plan. Mylan's Chairman Robert J. Coury commented, "We are very pleased to announce that Mylan is completing the $1 billion share repurchase plan previously approved by the Mylan N.V. Board of Directors. This return of capital to our shareholders comes at a time of positive momentum for Mylan, with the recent launches and approvals of several key products, our strong future growth expectations, and our belief that the diversified and unique platform we have built is substantially undervalued. In addition and pursuant to its agreement with Abbott (ABT) related to the Abbott EPD acquisition, Mylan has received notification from Abbott that it has sold its remaining 20.3 million shares of Mylan prior to year-end, removing a potential share overhang and consistent with Abbott's stated position that it did not intend to be a long-term shareholder." Coury continued, "Following our 2017 Annual General Meeting, we initiated an extensive outreach program to better understand shareholders' perspectives and increase their awareness of and appreciation for the unmatched strength and breadth of Mylan's global platform. We are committed to continuing our dialogue with shareholders and the larger investor community in an effort to continue to optimize Mylan's valuation."

MYL

Mylan

$44.54

0.23 (0.52%)

ABT

Abbott

$58.99

0.17 (0.29%)

  • 08

    Jan

  • 24

    Jan

  • 16

    Feb

MYL Mylan
$44.54

0.23 (0.52%)

12/22/17
CANT
12/22/17
NO CHANGE
CANT
Cantor ups price targets for Teva, Valeant, Mylan, Zoetis
Cantor Fitzgerald analyst Louise Chen raised her price target for Neutral-rated Teva (TEVA) to $18 from $10, for Overweight-rated Valeant (VRX) to $25 from $23, for Neutral-Mylan (MYL) to $41 from $34 and for Overweight-rated Zoetis (ZTS) to $85 from $80. Heading into 2018, the analyst believes Perrigo (PRGO) has the best setup in the Specialty Pharmaceuticals space. The company has given the most visibility on its outlook for 2018, Chen tells investors in a research note. She believes Zoetis, Mylan and Horizon Pharma (HZNP) also look good into next year.
01/02/18
LEER
01/02/18
INITIATION
Target $44
LEER
Market Perform
Mylan initiated with a Market Perform at Leerink
Leerink analyst Ami Fadia initiated Mylan with a Market Perform and $44 price target.
01/04/18
SBSH
01/04/18
UPGRADE
Target $24
SBSH
Buy
Teva upgraded to Buy from Neutral at Citi
Citi analyst Liav Abraham upgraded Teva Pharmaceutical to Buy and raised her price target for the shares to $24 from $16. The drugmaker closed yesterday up 2c to $19.13. The analyst "more constructive" on the Specialty Pharma group heading into 2018. More realistic expectations, along with pipeline catalysts set the stage for a potential inflection point for some of the stocks in 2018, Abraham tells investors in a research note on the sector. She believes Teva's risk/reward profile that is skewed to the upside over the near to medium as management executes on the recently announced cost cuts. Mylan (MYL) is Abraham's top pick for 2018.
01/04/18
SBSH
01/04/18
NO CHANGE
Target $58
SBSH
Buy
Citi adds Mylan to U.S. Focus List, ups target to $58
Citi analyst Liav Abraham added Mylan to her firm's U.S. Focus List and raised her price target for the shares to $58 from $48. Mylan is the analyst's top pick for 2018. The stock is best positioned in Specialty Pharma to benefit from the approval of complex generic products in the pipeline as well as from any potential disruption in the U.S. generic market, Abraham tells investors in a research note. She sees potential for multiple expansion and keeps a Buy rating on Mylan shares.
ABT Abbott
$58.99

0.17 (0.29%)

01/04/18
COWN
01/04/18
NO CHANGE
Target $70
COWN
Outperform
Dexcom selling off too much on Abbott news, says Cowen
Cowen analyst Doug Schenkel believes shares of Dexcom (DXCM) are down too much after Abbott (ABT) announced Medicare reimbursement for Libre. Given Libre's dosing claim, this development was expected, though it came three months earlier than expected, Schenkel tells investors in a research note. He believes a 10% selloff "appears disproportionate" on a three month timing swing on an expected event. The analyst keeps an Outperform rating on Dexcom with a $70 price target. The stock in late morning trading is down 11% to $51.86.
01/04/18
BARD
01/04/18
NO CHANGE
Target $58
BARD
Neutral
Risk to Dexcom estimates may be less than feared, says Baird
Baird analyst Jeff Johnson says his channel checks indicate Abbott's (ABT) Libre will be reimbursed by Centers for Medicare & Medicaid Services using the same codes as Dexcom's (DXCM) G5, meaning at the same monthly price of $250 per patient. The analyst has long believed superior technology, or G5 over Libre, will win out at price parity. As such, he believes today's news may not be create as much near-term risk to Dexcom numbers as investors believe. The analyst, however, keeps a Neutral rating on Dexcom shares, despite today's 11% selloff. He believes longer-term CMS and commercial payer questions remain.
01/05/18
LEER
01/05/18
NO CHANGE
Target $75
LEER
Outperform
Dexcom pricing risk less bad than feared, says Leerink
Leerink analyst Danielle Antalffy says her conversation with a specialist reinforced her view that Dexcom (DXCM) will continue to warrant at least some price premium to Abbott's (ABT) Libre given its alert and alarm capabilities and what is presumably better outcomes for patients. The analyst continues to recommend buying Dexcom on yesterday's, particularly for investors with at least a six month time horizon. She reiterates an Outperform rating on the shares with a $75 price target. Antalffy sees the company's pricing risk as less bad than feared following yesterday's news of Abbott securing Medicaid approval sooner than expected for its Freestyle Libre.
01/05/18
WBLR
01/05/18
NO CHANGE
WBLR
Outperform
William Blair sees Dexcom remaining 'product-of-choice' in glucose monitoring
William Blair analyst Margaret Kaczor believes Dexcom (DXCM) will remain the "product-of-choice" in glucose monitoring after Abbott (ABT) received Medicare approval for its Freestyle Libre Flash. While the approval comes six to nine months earlier than anticipated, Abbott's broader presence will likely expand patient awareness, Kaczor tells investors in a research note. She believes Dexcom is well positioned given its alerts and alarms in this "more vulnerable patient population." The analyst keeps an Outperform rating on the shares following yesterday's selloff.

TODAY'S FREE FLY STORIES

HAWK

Blackhawk

$45.20

-0.05 (-0.11%)

04:48
01/23/18
01/23
04:48
01/23/18
04:48
Downgrade
Blackhawk rating change  »

Blackhawk downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

02:45
01/23/18
01/23
02:45
01/23/18
02:45
General news
FX Update: The dollar gained on the Senate vote »

FX Update: The dollar…

02:25
01/23/18
01/23
02:25
01/23/18
02:25
General news
BoJ's Kuroda sounded dovish at his post-meeting press conference »

BoJ's Kuroda sounded…

CENT

Central Garden & Pet

$37.82

0.09 (0.24%)

20:37
01/22/18
01/22
20:37
01/22/18
20:37
Upgrade
Central Garden & Pet rating change at KeyBanc »

Central Garden & Pet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPAR

Inter Parfums

$45.90

-1.9 (-3.97%)

20:33
01/22/18
01/22
20:33
01/22/18
20:33
Downgrade
Inter Parfums rating change at KeyBanc »

Inter Parfums downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$148.14

0.78 (0.53%)

, PG

Procter & Gamble

$91.89

0.82 (0.90%)

20:25
01/22/18
01/22
20:25
01/22/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

JNJ

Johnson & Johnson

$148.14

0.78 (0.53%)

PG

Procter & Gamble

$91.89

0.82 (0.90%)

VZ

Verizon

$53.46

1.55 (2.99%)

KMB

Kimberly-Clark

$116.91

1.42 (1.23%)

TRV

Travelers

$139.35

1.5 (1.09%)

FITB

Fifth Third

$32.77

0.27 (0.83%)

HBAN

Huntington Bancshares

$16.03

0.22 (1.39%)

WAT

Waters

$214.77

4.05 (1.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 06

    Feb

  • 13

    Feb

  • 16

    Feb

  • 08

    Mar

SSNLF

Samsung

19:26
01/22/18
01/22
19:26
01/22/18
19:26
Hot Stocks
Samsung says new tariff 'great loss' for American consumers, workers »

In reaction to a final…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

FTK

Flotek

$5.71

0.07 (1.24%)

19:23
01/22/18
01/22
19:23
01/22/18
19:23
Hot Stocks
Flotek expands lines of chemistry technologies »

Flotek Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

ACLS

Axcelis

19:22
01/22/18
01/22
19:22
01/22/18
19:22
Upgrade
Axcelis rating change at Stifel »

Axcelis upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

W

Wayfair

$90.64

2.8 (3.19%)

19:22
01/22/18
01/22
19:22
01/22/18
19:22
Downgrade
Wayfair rating change at Stifel »

Wayfair downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

EPE

EP Energy

$2.48

0.17 (7.36%)

19:00
01/22/18
01/22
19:00
01/22/18
19:00
Conference/Events
EP Energy to hold a conference call »

Management discusses its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

BRSS

Global Brass and Copper

$33.30

-0.55 (-1.62%)

18:47
01/22/18
01/22
18:47
01/22/18
18:47
Hot Stocks
Global Brass and Copper reports oil spill at Somers Thin Strip plant »

Somers Thin Strip, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$227.58

7.12 (3.23%)

, DIS

Disney

$111.10

0.51 (0.46%)

18:38
01/22/18
01/22
18:38
01/22/18
18:38
Hot Stocks
Netflix doesn't see Disney-Fox deal as a direct threat »

Says Disney (DIS) and Fox…

NFLX

Netflix

$227.58

7.12 (3.23%)

DIS

Disney

$111.10

0.51 (0.46%)

FOX

21st Century Fox

$36.96

0.7 (1.93%)

FOXA

21st Century Fox

$37.31

0.66 (1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

  • 06

    Feb

  • 07

    Feb

  • 07

    Feb

T

AT&T

$37.87

0.66 (1.77%)

, TWX

Time Warner

$94.00

0.64 (0.69%)

18:37
01/22/18
01/22
18:37
01/22/18
18:37
Periodicals
Judge orders DOJ to seek consent to give data to AT&T, Time Warner, Reuters says »

Judge Richard Leon, who…

T

AT&T

$37.87

0.66 (1.77%)

TWX

Time Warner

$94.00

0.64 (0.69%)

DIS

Disney

$111.10

0.51 (0.46%)

FOX

21st Century Fox

$36.96

0.7 (1.93%)

FOXA

21st Century Fox

$37.31

0.66 (1.80%)

VIA

Viacom

$39.30

0.1 (0.26%)

VIAB

Viacom

$33.94

0.58 (1.74%)

DISCA

Discovery

$26.33

0.62 (2.41%)

SNI

Scripps Networks

$88.77

0.27 (0.31%)

CMCSA

Comcast

$42.89

0.39 (0.92%)

CMCSK

Comcast

CHTR

Charter

$370.25

4.2 (1.15%)

ATUS

Altice USA

$21.90

0.6 (2.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

  • 02

    Feb

  • 06

    Feb

  • 07

    Feb

  • 07

    Feb

  • 08

    Feb

  • 08

    Feb

  • 12

    Feb

  • 27

    Feb

NFLX

Netflix

$227.58

7.12 (3.23%)

18:25
01/22/18
01/22
18:25
01/22/18
18:25
Hot Stocks
Netflix says it has a ways to go to hit 60M U.S. subscribers »

Says has a ways to go to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

BIVV

Bioverativ

$103.79

39.68 (61.89%)

, SNY

Sanofi

$43.20

-1.4 (-3.14%)

18:15
01/22/18
01/22
18:15
01/22/18
18:15
Downgrade
Bioverativ, Sanofi rating change at Jefferies »

Bioverativ downgraded to…

BIVV

Bioverativ

$103.79

39.68 (61.89%)

SNY

Sanofi

$43.20

-1.4 (-3.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 14

    Feb

  • 16

    Feb

  • 08

    Mar

  • 25

    Mar

  • 25

    Apr

  • 02

    May

ECR

Eclipse Resources

$2.33

0.05 (2.19%)

18:12
01/22/18
01/22
18:12
01/22/18
18:12
Conference/Events
Eclipse Resources to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$227.58

7.12 (3.23%)

18:10
01/22/18
01/22
18:10
01/22/18
18:10
Hot Stocks
Netflix says Asia market projects 'well' »

Says very pleased with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

STLD

Steel Dynamics

$46.57

0.15 (0.32%)

18:06
01/22/18
01/22
18:06
01/22/18
18:06
Hot Stocks
Steel Dynamics CEO says domestic inventory levels moderated »

Steel Dynamics CEO Mark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

STLD

Steel Dynamics

$46.57

0.15 (0.32%)

18:04
01/22/18
01/22
18:04
01/22/18
18:04
Earnings
Steel Dynamics reports Q4 EPS 54c excluding items, consensus 52c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

IMI

Intermolecular

$1.61

0.14 (9.52%)

18:02
01/22/18
01/22
18:02
01/22/18
18:02
Hot Stocks
Intermolecular and SITRI expand alliance to address Chinese market »

Intermolecular and SITRI…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

EXFO

EXFO Inc.

$4.35

-0.05 (-1.14%)

, CHL

China Mobile

$51.97

0.45 (0.87%)

18:01
01/22/18
01/22
18:01
01/22/18
18:01
Hot Stocks
EXFO partners with China Mobile to prepare network for IoT »

EXFO Inc. (EXFO)…

EXFO

EXFO Inc.

$4.35

-0.05 (-1.14%)

CHL

China Mobile

$51.97

0.45 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$111.12

-1.84 (-1.63%)

18:00
01/22/18
01/22
18:00
01/22/18
18:00
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jan

SFNC

Simmons First National

$59.50

0.35 (0.59%)

18:00
01/22/18
01/22
18:00
01/22/18
18:00
Earnings
Simmons First National reports Q4 core EPS 97c, consensus 88c »

Reports Q4 core net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

WHR

Whirlpool

$166.65

-0.88 (-0.53%)

, SSNLF

Samsung

17:59
01/22/18
01/22
17:59
01/22/18
17:59
Hot Stocks
Whirlpool chairman praises Trump's move to establish tariff on washing machines »

Whirlpool (WHR) chairman…

WHR

Whirlpool

$166.65

-0.88 (-0.53%)

SSNLF

Samsung

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 30

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.